Sabby Volatility Fund Discloses 177,513 Share Stake in Bluejay Diagnostics
Ticker: BJDX · Form: SC 13G · Filed: Jan 3, 2024 · CIK: 1704287
| Field | Detail |
|---|---|
| Company | Bluejay Diagnostics, INC. (BJDX) |
| Form Type | SC 13G |
| Filed Date | Jan 3, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, investor-update, stake-disclosure
TL;DR
**Sabby Volatility Fund just revealed a 177,513 share stake in Bluejay Diagnostics.**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands-based entity, reported on January 3, 2024, that it beneficially owns 177,513 shares of Bluejay Diagnostics, Inc. (BJDX) Common Stock as of December 31, 2023. This represents a significant stake, indicating a notable investor's belief in the company's future. For current or prospective shareholders, this filing signals that a professional investment fund sees value in BJDX, potentially boosting confidence or suggesting further scrutiny into the fund's investment thesis.
Why It Matters
This filing shows a major investment fund, Sabby Volatility Warrant Master Fund, Ltd., has taken a significant position in Bluejay Diagnostics, which can be seen as a vote of confidence in the company's prospects.
Risk Assessment
Risk Level: low — This filing indicates a new institutional investment, which generally reduces risk by signaling external validation of the company's value.
Analyst Insight
A smart investor would research Sabby Volatility Warrant Master Fund, Ltd.'s investment strategy and track record to understand their rationale for investing in Bluejay Diagnostics, and then evaluate BJDX's fundamentals to see if it aligns with their own investment goals.
Key Numbers
- 177,513 — Shares Beneficially Owned (This is the total number of Bluejay Diagnostics shares Sabby Volatility Warrant Master Fund, Ltd. reported owning.)
- 095633103 — CUSIP Number (This unique identifier confirms the specific class of securities (Common Stock) of Bluejay Diagnostics, Inc. that was reported.)
Key Players & Entities
- Bluejay Diagnostics, Inc. (company) — the subject company whose shares were acquired
- Sabby Volatility Warrant Master Fund, Ltd. (company) — the reporting person who acquired the shares
- Sabby Management, LLC (company) — the entity that filed the SC 13G on behalf of the fund
- 177,513 (dollar_amount) — number of shares beneficially owned
- December 31, 2023 (date) — date of the event requiring the filing
- January 3, 2024 (date) — date the filing was made
Forward-Looking Statements
- Other institutional investors may take notice of Sabby Volatility Warrant Master Fund, Ltd.'s position and conduct their own due diligence on Bluejay Diagnostics, potentially leading to increased trading volume. (Bluejay Diagnostics, Inc.) — medium confidence, target: Q1 2024
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is Sabby Volatility Warrant Master Fund, Ltd., as stated in Item 1 of the filing.
What is the subject company whose shares are being reported?
The subject company is Bluejay Diagnostics, Inc., as indicated in the 'Name of Issuer' section of the filing.
How many shares of Bluejay Diagnostics, Inc. Common Stock does the reporting person beneficially own?
The reporting person, Sabby Volatility Warrant Master Fund, Ltd., beneficially owns 177,513 shares, as shown in Row 9 of the cover page.
What was the date of the event that triggered this SC 13G filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the checked box on the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 3, 2024 regarding Bluejay Diagnostics, Inc. (BJDX).